Tim Buckley elected to Pfizer’s Board of Directors
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
Subscribe To Our Newsletter & Stay Updated